Related Experiment Video
Updated: Jul 14, 2026
A Technique to Screen American Beech for Resistance to the Beech Scale Insect (Cryptococcus fagisuga Lind.)
Published on: May 27, 2014
BAY-43-9006 Bayer/Onyx
1Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, East Fifth Street, Greenville, NC 27858-4553, USA.
Abstract:
Bayer and Onyx are developing BAY-43-9006, an oral cytostatic Raf kinase inhibitor for the potential treatment of colorectal and breast cancers, hepatocellular carcinoma and non-small-cell lung cancer, in addition to acute myelogenous leukemia, myelodysplastic syndrome and other cancers. A US IND was filed in May 2000 and by February 2003 BAY-43-9006 was in phase II trials, with phase III trials expected to begin later in 2003.
Insights
BAY-43-9006 is an oral Raf kinase inhibitor being developed for multiple cancers, including colorectal, breast, and lung cancer. Clinical trials are progressing, with Phase III studies anticipated soon.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- BAY-43-9006 is an investigational oral Raf kinase inhibitor.
- It targets multiple cancer types, including solid tumors and hematologic malignancies.
Purpose of the Study:
- To evaluate the safety and efficacy of BAY-43-9006 in various cancers.
- To advance BAY-43-9006 through clinical development.
Main Methods:
- Development by Bayer and Onyx.
- Filing of a US Investigational New Drug (IND) application in May 2000.
- Progression into Phase II clinical trials by February 2003.
Main Results:
- BAY-43-9006 is an oral cytostatic agent.
- The drug is being investigated for colorectal cancer, breast cancer, hepatocellular carcinoma, non-small-cell lung cancer, acute myelogenous leukemia, and myelodysplastic syndrome.
Conclusions:
- BAY-43-9006 shows potential for treating a range of cancers.
- Further clinical evaluation, including Phase III trials, is planned.
